NLRP3 inhibitors for the treatment of inflammatory skin disorders
US10857123B2 · kind B2 · utility
10Cited by
0References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 25, 2017 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | Jan 25, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of an NLRP3 inhibitor compound is described in the treatment of inflammatory skin disorders, in particular psoriasis and atopic dermatitis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.